Dr. Joshua Liao discusses how insights from behavioral science can be used to mitigate the unintended consequences of travel bans aimed at controlling Covid-19.
Manufacturers in India are gearing up to produce generic versions of Pfizer and Merck’s antivirals and can make millions of pills a month. They just need regulators to give them the okay.
The company, which raised $300 million at a $4.8 billion valuation this month, changed the status of more than 200 employees from salaried to hourly workers in August and made their health insurance contingent on quotas in 2022.
A once-in-a-generation explosion in entrepreneurship is taking place as founders bet on themselves in record numbers. MainStreet U.S.A is back in business—and stronger than ever.
Infectious disease expert Dr. Mark Kortepeter discusses the need for a better U.S. system to screen for travel-related illnesses and the pathogens stored in laboratory freezers, among other measures.